Scribd Logo
Upload

Welcome to Scribd!

  • 332 views

    Tranexamic Acid

    Uploaded by

    Irish Ivy Vibeth
    Tranexamic acid (brand names Cyklokapron and Lysteda) is a fibrinolysis inhibitor used as a hemostatic agent. It works by competitively inhibiting the activation of plasminogen to reduce the breakdown of fibrin clots. This decreases bleeding. However, it can cause side effects like nausea, vomiting, diarrhea, and hypotension. It may also increase risks of thromboembolic events like pulmonary embolism. When administering tranexamic acid, nurses monitor patients for bleeding, vital signs, neurological status, and thromboembolic complications before, during, and after treatment. They educate patients to report bleeding recurrence or thromboembolic symptoms and move slowly to prevent hypotension.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Tranexamic Acid

    Uploaded by

    Irish Ivy Vibeth
    332 views2 pages
    Tranexamic acid (brand names Cyklokapron and Lysteda) is a fibrinolysis inhibitor used as a hemostatic agent. It works by competitively inhibiting the activation of plasminogen to reduce the breakdown of fibrin clots. This decreases bleeding. However, it can cause side effects like nausea, vomiting, diarrhea, and hypotension. It may also increase risks of thromboembolic events like pulmonary embolism. When administering tranexamic acid, nurses monitor patients for bleeding, vital signs, neurological status, and thromboembolic complications before, during, and after treatment. They educate patients to report bleeding recurrence or thromboembolic symptoms and move slowly to prevent hypotension.

    Original Description:

    Drug study

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Tranexamic acid (brand names Cyklokapron and Lysteda) is a fibrinolysis inhibitor used as a hemostatic agent. It works by competitively inhibiting the activation of plasminogen to reduce the breakdown of fibrin clots. This decreases bleeding. However, it can cause side effects like nausea, vomiting, diarrhea, and hypotension. It may also increase risks of thromboembolic events like pulmonary embolism. When administering tranexamic acid, nurses monitor patients for bleeding, vital signs, neurological status, and thromboembolic complications before, during, and after treatment. They educate patients to report bleeding recurrence or thromboembolic symptoms and move slowly to prevent hypotension.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    332 views2 pages

    Tranexamic Acid

    Uploaded by

    Irish Ivy Vibeth
    Tranexamic acid (brand names Cyklokapron and Lysteda) is a fibrinolysis inhibitor used as a hemostatic agent. It works by competitively inhibiting the activation of plasminogen to reduce the breakdown of fibrin clots. This decreases bleeding. However, it can cause side effects like nausea, vomiting, diarrhea, and hypotension. It may also increase risks of thromboembolic events like pulmonary embolism. When administering tranexamic acid, nurses monitor patients for bleeding, vital signs, neurological status, and thromboembolic complications before, during, and after treatment. They educate patients to report bleeding recurrence or thromboembolic symptoms and move slowly to prevent hypotension.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 2

    Brand name: Cyklokapron/Lysteda

    Generic name: Tranexamic Acid

    Classification:
     Therapeutic: hemostatic agents
     Pharmacologic: fibrinolysis inhibitors

    Mechanism of action: Tranexamic acid competitively inhibits activation of plasminogen


    thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that
    degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant
    factors V and VIII.
    In patients with hereditary angioedema, inhibition of the formation and activity of
    plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-
    induced activation of the first complement protein (C1).

    Adverse effect:
     Hypersensitivity reactions
     Cerebrovascular infarction
     Myocardial infarction
     Pulmonary embolism

    Side effect:
     Nausea
     Vomiting
     Diarrhea
     Hypotension
     Thromboembolic, e.g., arterial, venous, embolic;
     Neurologic, e.g., visual impairment, convulsions, headache, mental status
    changes; myoclonus;
     Rash

    Nursing responsibilities:
    Before:
     Monitor blood pressure, pulse, and respiratory status as indicated by severity of
    bleeding.
    Rationale: This is to ensure that the patient is in a steady state where the blood
    pressure is within normal levels, the pulse rate are not decreasing over time
    and the respiratory system are supplying enough oxygen.
     Monitor for overt bleeding every 15–30 min.
    Rationale: To determine excessive bleeding and effectivity of drug.
     Monitor neurologic status (pupils, level of consciousness, motor activity) in
    patients with subarachnoid hemorrhage.
    Rationale: Subarachnoid hemorrhage is a life threatening form of stroke and
    therefore requires intensive care and observation.
     Assess for thromboembolic complications.(especially in patients with history).
    Notify physician of positive Homans’ sign, leg pain hemorrhage, edema,
    hemoptysis, dyspnea, or chest pain.
    Rationale: A thromboembolic complication can break loose and cause a
    serious problem in the lung, called a pulmonary embolism, or a heart attack or
    stroke if not treated immediately.
     Monitor platelet count and clotting factors prior to and periodically throughout
    therapy in patients with systemic fibrinolysis.
    Rationale: To ensure that the Coagulation cascade within the patients body,
    there are no excessive clotting or bleeding that happens throughout the body.
    During:
     Stabilize IV catheter. Monitor site closely.
    Rationale: To minimize thrombophlebitis.
    After:
     Instruct patient to notify the nurse immediately if bleeding recurs or if
    thromboembolic symptoms develop.
    Rationale: In order for the nurse to possibly make immediate action to resolve
    the bleeding.
     Caution patient to make position changes slowly.
    Rationale: To avoid orthostatic hypotension.

    You might also like